Dr. Shaker Dakhil has been recognized as an author in a trial of patients with diagnosed metastatic clear cell renal cell carcinoma (mRCC) in the Journal of Clinical Oncology, one of the most respected publications in the field (the article is available in its entirety below). This manuscript has been designated as Rapid Communication, a highly distinguished category reserved for papers judged to have special impact to the broad clinical readership of the JCO. The trial has concluded and thus brought about new information on treatments for untreated mRCC. The Cancer Center of Kansas is so proud to be one of only 46 cancer research programs in the nation currently funded by the National Cancer Institute Community Oncology Research Program (NCORP). NCORP is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems and conduct high quality trials that are aimed to better understand oncology through studies that work to prevent and/ or care for cancer.
For additional resource information visit https://ncorp.cancer.gov/ or http://jco.ascopubs.org/
Metastatic clear cell renal cell carcinoma trial
